#### REVVITY INC.

ISIN: US7140461093 WKN: 714046109 Asset Class: Stock



#### **Company Profile**

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,001,091,000		3,288,558,000		2,440,780,000	
Common stock capital		123,426,000		126,300,000		126,241,000
Fixed assets	10,563,574,000		10,841,297,000		12,559,774,000	
Equity capital of a company		7,872,739,000		7,382,876,000		7,141,245,000
Cash and cash equivalents	914,373,000		455,398,000		619,337,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		1,450,463,000		1,544,483,000		1,213,744,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		4,241,463,000		5,202,496,000		6,645,565,000
Different income		-		-		-
Other liabilities		930,946,000		1,109,181,000		1,480,469,000
Total assets	13,564,665,000	13,564,665,000	14,129,855,000	14,129,855,000	15,000,554,000	15,000,554,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	11,500	16,700	16,700
Equity ratio	58.04%	52.25%	47.61%
Debt-equity ratio	72.30%	91.39%	110.06%

#### **Others**

	2023	2022	2021
Tax Expense Rate	1.90%	21.35%	26.30%

# **REVVITY INC.**

ISIN: US7140461093 WKN: 714046109 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	2,750,571,000	3,311,822,000	5,067,169,000
Net income	179,503,000	512,676,000	943,283,000
EBIT	196,994,657	706,769,939	1,296,434,711
Operating income before taxes	182,976,000	651,837,000	1,279,886,000
Cash Flow	91,272,000	679,810,000	1,410,750,000
Net interest income	-26,682,000	-100,366,000	-99,887,000
Research and development expenses	216,578,000	221,617,000	274,969,000
Income taxes	3,473,000	139,161,000	336,603,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	224,734	186,335	285,097

## **Board of Directors**

Members of Management Board		
Alexis Michas	Chairman of Board of Directors	
Franklin Witney	Member of Board of Directors	
Michelle McMurry-Heath	Member of Board of Directors	
Peter Barrett	Member of Board of Directors	
Sophie Vandebroek	Member of Board of Directors	
Sylvie Grégoire	Member of Board of Directors	
Michael Klobuchar	Member of Board of Directors	
Michel Vounatsos	Member of Board of Directors	
Pascale Witz	Member of Board of Directors	
Samuel Chapin	Member of Board of Directors	
Prahlad Singh	Chairman of Managing Board	
Anita Gonzales	Member of Executive Committee	
Maxwell Krakowiak	Member of Executive Committee	